The novel depot of buprenorphine propionate has a long-acting effect on physical dependence on morphine

Drug Development Research

Volumn 67, Issue 5, 2006, Pages 462-469

  Liu, Kuo Sheng ^a,b   Lin, Ching Nan ^b   Shieh, Ja Ping ^b   Chu, Chin Chen ^b   Kuei, Chun Hsiung ^a   Wang, Jhi Joung ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Buprenorphine; Dependence; Depot; Long acting; Morphine

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PROPIONATE; LONG ACTING DRUG; MORPHINE; SESAME SEED OIL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPOT FORMULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; EVALUATION; MALE; MORPHINE ADDICTION; MOUSE; MOUSE STRAIN; NONHUMAN;

EID: 33749034460     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20107     Document Type: Article

References (29)

1. Allen LVJ, Popovich NG, Ansel HC. 2005a. Dosage form design: biopharmaceutic and pharmacokinetics considerations. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edition. Philadelphia: Lippincott Williams & Wilkins, p 142-185.
2. Allen LVJ, Popovich NG, Ansel HC. 2005b. Solid oral modified-release dosage forms and drug delivery system. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edition. Philadelphia: Lippincott Williams & Wilkins, p 260-275.
3. Allen LVJ, Popovich NG, Ansel HC. 2005c. Parenterals. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edition. Philadelphia: Lippincott Williams & Wilkins. p 443-505.
4. Assadi SM, Hafezi M, Mokri A, Razzaghi EM, Ghaeli P. 2004. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J Subst Abuse Treat 27:75-82.
5. Barnett PG, Rodgers JH, Bloch DA. 2001. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96:683-690.
6. Bickel WK. Amass L. 1995. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3:477-489.
7. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. 1988. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78.
8. Brewer C. 1997. Ultra-rapid, antagonist-precipitated opiate detoxification under general anesthesia or sedation. Addict Biol 2:291-302.
9. Cheskin LJ, Fudala PJ, Johnson RE. 1994. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 36:115-121.
10. Davids E, Gastpar M. 2004. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 14:209-216.
11. El-kadi AOS, Sharif SI. 1994. The influence of various experimental conditions on the expression of naloxone-induced withdrawal symptoms in mice. Gen Pharmacol 25:1505-1510.
12. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. 2002. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 28:231-241.
13. Heel RC, Brogden RN, Speight TM, Avery GS. 1979. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drug 17:81-110.
14. Janiri L, Mannelli P, Persioo AM, Serretti A, Tempesta E. 1994. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 36:139-145.
15. Jasinski DR, Fudula PJ, Johnson RE. 1989. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 45:513-519.
16. Kest B, Palmese CA, Hopkins E, Adler M, Juni A. 2001. Assessment of acute and chronic morphine dependence in male and female mice. Pharmacol Biochem Behav 70:149-156.
17. Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS. 2002. Naloxone- precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115:463-469.
18. Kosten TR. 2003. Buprenorphine for opioid detoxification. Addict Disord Ther Treatment 2:107-112.
19. Kosten TR, Fiellin DA. 2004. Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13:S1-S7.
20. Law FD, Myles JS, Daglish MRC, Nutt DJ. 2004. The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiat 16:246-274.
21. Liu KS, Hu OYP, Ho ST, Tzeng JI, Chen YW, Wang JJ. 2004. Antinociceptive effect of a novel long-acting nalbuphine preparation. Br J Anaesth 92:712-715.
22. Liu SY, Liu KS, Kuei CH, Tzeng JI, Ho ST, Wang JJ. 2005. Simultaneous determination of buprenorphine and its prodrug, buprenorphine propionate, by high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies in rabbits. J Chromatogr Biomed Appl 818:233-239.
23. Roy SD, Roos E, Sharma K. 1994. Transdermal delivery of buprenorphine through cadaver skin. J Pharm Sci 83:126-130.
24. Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of injection depot formulation of buprenorphine: placebo comparison. Addiction 99:1439-1449.
25. Sobel BFX, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE. 2004. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 73:11-22.
26. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. 1995. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 12:1526-1529.
27. Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. 1996. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 13:1519-1523.
28. Testa B, Mayer JM. 2003. Introduction: metabolic hydrolysis and prodrug design. In: Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology. Zurich, Switzerland: Verlag Helvetica Chimica Acta. p 1-11.
29. Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. 1999. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend 56:181-190.